logo

Lumiradx Limited (LMDX)



Trade LMDX now with
  Date
  Headline
8/18/2022 7:25:50 AM LumiraDx Q2 Loss Per Share $0.58 Vs Loss $0.12 Last Year
7/21/2022 8:40:07 AM LumiraDx Prices Underwritten Public Offering Of 43 Mln Shares At $1.75/shr
7/19/2022 9:12:11 AM LumiraDx Commences Underwritten Public Offering Of 40 Mln Common Shares
6/9/2022 8:39:37 AM LumiraDx Achieves CE Mark For COVID-19 Antigen Test On Amira
5/20/2022 5:42:40 AM LumiraDx Receives WHO Emergency Use Listing For SARS-CoV-2 Ag Test
5/19/2022 9:01:46 AM LumiraDx Announces SARS-CoV-2 Ag Ultra Test Achieved CE Marking
3/10/2022 6:11:03 AM LumiraDx Q4 Loss Per Share $0.15 Vs Loss $0.51 Last Year
1/14/2022 6:20:29 AM LumiraDx Lab Analysis Confirms COVID-19 Antigen Test Detects Omicron Variant
1/11/2022 6:35:30 AM LumiraDx Says C-reactive Protein Test Achieves CE Marking
12/23/2021 6:07:49 AM LumiraDx: SARS-CoV-2 & Flu A/B Antigen Test Achieves CE Marking
12/1/2021 8:29:07 AM FDA Reissues LumiraDx Fast Lab Solutions' EUA For SARS CoV-2 RNA STAR Complete Molecular Reagents
11/10/2021 6:23:15 AM LumiraDx Reports Q3 Net Income Of $84.8 Mln Or $0.46/shr